The development of medical image databases has been largely a private activity to date, lacking the rigor and standards that would allow these repositories to serve as reference models for research, including drug development. This is changing, however, as more organizations, including the U.S. National Institutes of Health and the European Federation for Medical Informatics, join the effort. But significant challenges remain, speakers said at a special session Saturday.
The development of medical image databases has been largely a private activity to date, lacking the rigor and standards that would allow these repositories to serve as reference models for research, including drug development. This is changing, however, as more organizations, including the U.S. National Institutes of Health and the European Federation for Medical Informatics, join the effort. But significant challenges remain, speakers said at a special session Saturday.
The incredible variety of imaging findings has proved to be an obstacle as researchers struggle to annotate reference images appropriately. A group at the NIH used a consensus process to annotate images with lung nodules but found it slow going, said Laurence P. Clarke, Ph.D., of the institute's cancer imaging program.
Resources have also proved to be a problem, according to Alexander Horsch, Ph.D., of the University of Munich and a member of the European Federation for Medical Informatics (EFMI). The federation established a workgroup in 2002 to pursue a reference image database. Since then, awareness of the need for such a database has grown, but the commitment to contribute has been limited.
"Everyone wants to get, nobody wants to give," Horsch said.
Two factors are driving the interest in reference image databases: the need for standards against which image processing strategies can be evaluated, and the use of imaging as an end point in drug development.
The benefits of a reference image database could be considerable, Clarke said. They include benchmarking for common cases, accelerated development of computer-assisted detection, objective assessment of therapies, greater confidence in clinical decisions, streamlined drug development, and better informed coverage decisions.
The National Cancer Institute launched its Lung Image Database Consortium project in 2001. This year, it reached a cooperative agreement with the American College of Radiology Imaging Network to share some of the clinical trial data. It has begun to speed up data collection and expects to complete the project with 400 cases in September 2006, Clarke said.
The database is intended to permit benchmarking of CAD for lung nodule detection and diagnosis in a screening and early diagnosis context. A recently established public-private partnership involving the NCI, FDA, industry, and the Foundation for the National Institutes of Health will build on the results.
Research by the EFMI working group identified other databases under development. The 10 largest include eight commercial databases, one with 1.2 million images. They generally could not be validated, however, and would not serve as reference databases.
A group of 10 smaller medical image databases comes closer to what the EFMI is seeking, Horsch said. One is the NCI's lung image database. Two are devoted to breast cancer: the Digital Database for Screening Mammography (U.S.) and one run by the Mammographic Imaging Analysis Society (U.K.). Three are committed to brain imaging: the Simulated Brain Database, the Biomedical Informatics Research Network, and the Laboratory of Neuro Imaging (all in the U.S.). The Pap Smear Tutorial (Denmark) addresses cervical cancer, and the Medical Image Reference Center (Japan) focuses on cancer and cardiovascular diseases.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.